Midostaurin in the treatment of a patient with acute myeloid leukaemia with FLT3-TKD mutation and NPM1 mutation.
- Published in:
- Hematology in Clinical Practice, 2022, v. 22, n. 1, p. 37, doi. 10.5603/HCP.2022.0006
- By:
- Publication type:
- Article
Works matching IS 27201015 AND DT 2022 AND VI 22 AND IP 1
Results: 6
1
2
Treatment of a patient with acute myeloid leukaemia with FLT3-ITD mutation.
- Published in:
- Hematology in Clinical Practice, 2022, v. 22, n. 1, p. 31, doi. 10.5603/HCP.2022.0005
- By:
- Publication type:
- Article
3
Efficacy of midostaurin combined with intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation in a patient with NPM1 and FLT3-TKD mutated acute myeloid leukaemia with clinical high-risk features.
- Published in:
- Hematology in Clinical Practice, 2022, v. 22, n. 1, p. 23, doi. 10.5603/HCP.2022.0004
- By:
- Publication type:
- Article
4
IGHV mutational status and the choice of first-line therapy for patients with chronic lymphocytic leukaemia.
- Published in:
- Hematology in Clinical Practice, 2022, v. 22, n. 1, p. 7, doi. 10.5603/HCP.2022.0003
- By:
- Publication type:
- Article
5
Polyserositis (pericarditis and bilateral pleural effusion) after COVID-19 mRNA vaccine.
- Published in:
- Hematology in Clinical Practice, 2022, v. 22, n. 1, p. 15, doi. 10.5603/HCP.2022.0001
- By:
- Publication type:
- Article
6
Haematological manifestations of X-linked lymphoproliferative disease.
- Published in:
- Hematology in Clinical Practice, 2022, v. 22, n. 1, p. 1, doi. 10.5603/HCP.a2022.0002
- By:
- Publication type:
- Article